Literature DB >> 10758961

Lipoprotein(a) is a risk factor for occurrence of acute myocardial infarction in patients with coronary vasospasm.

K Miwa1, K Nakagawa, N Yoshida, Y Taguchi, H Inoue.   

Abstract

OBJECTIVES: The purpose of this study is to determine whether lipoprotein(a) (Lp[a]) is an independent risk factor for coronary spasm and occurrence of acute myocardial infarction (AMI) in patients with coronary spasm.
BACKGROUND: Although elevated serum Lp(a) levels are known to be associated with coronary atherosclerosis and AMI, the association between the elevated level of this lipoprotein and coronary spasm remains to be elucidated.
METHODS: Serum Lp(a) levels were measured using a latex immunoassay in 77 patients with coronary spasm but without a significant (>75%) fixed coronary stenosis, including 16 with prior myocardial infarction (MI), in 177 patients with a fixed stenosis but without rest angina, including 114 with prior MI and in 81 control subjects without coronary artery disease.
RESULTS: The serum Lp(a) level in patients with coronary spasm (median; 17 mg/dl) was higher (p < 0.01) than in control subjects (12 mg/dl) but lower (p < 0.01) than in patients with a fixed stenosis (23 mg/dl). The incidence of subjects with higher (>25 mg/dl) serum Lp(a) levels was higher in patients with a fixed stenosis (46%, p < 0.01) but not in patients with coronary spasm (27%), compared with control subjects (21%). Among the patients with coronary spasm, the incidence of higher Lp(a) levels was higher in patients with than in those without a history of prior MI (56% vs. 21%, p < 0.05). The patients with higher Lp(a) levels had a higher incidence of prior MI than those without (41% vs. 13%, p < 0.05). The multivariate analysis confirmed that higher serum Lp(a) level is an independent determinant for prior MI in these patients (odds ratio, 4.19; 95%, confidence interval, 1.03 to 17.00).
CONCLUSIONS: Elevated serum level of Lp(a) was found to be associated with a history of prior MI in patients with coronary spasm, suggesting that Lp(a) may play an important role in the genesis of thrombotic coronary occlusion and the occurrence of AMI subsequent to coronary spasm.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10758961     DOI: 10.1016/s0735-1097(00)00550-7

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  6 in total

Review 1.  Clinical Application of Genetic Testing in Heart Failure.

Authors:  Ana Morales; Ray Hershberger
Journal:  Curr Heart Fail Rep       Date:  2017-12

2.  Age-related effects of regular physical activity on hemostatic factors in men.

Authors:  Jun Sugawara; Koichiro Hayashi; Sumiko Kurachi; Taku Tanaka; Takashi Yokoi; Kotoku Kurachi
Journal:  J Thromb Thrombolysis       Date:  2007-09-10       Impact factor: 2.300

Review 3.  Potential of lipoproteins as biomarkers in acute myocardial infarction.

Authors:  Haseeb Ahmad Khan; Aishah Ekhzaimy; Isra Khan; Meena Kishore Sakharkar
Journal:  Anatol J Cardiol       Date:  2017-07       Impact factor: 1.596

Review 4.  Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction.

Authors:  Enas A Enas; Basil Varkey; T S Dharmarajan; Guillaume Pare; Vinay K Bahl
Journal:  Indian Heart J       Date:  2019-03-20

Review 5.  The Biochemical Markers Associated with the Occurrence of Coronary Spasm.

Authors:  Liang Li; Yong-Ping Jin; Shu-Dong Xia; Chao Feng
Journal:  Biomed Res Int       Date:  2019-09-17       Impact factor: 3.411

6.  Apolipoprotein (a)/Lipoprotein(a)-Induced Oxidative-Inflammatory α7-nAChR/p38 MAPK/IL-6/RhoA-GTP Signaling Axis and M1 Macrophage Polarization Modulate Inflammation-Associated Development of Coronary Artery Spasm.

Authors:  Yen-Kuang Lin; Chi-Tai Yeh; Kuang-Tai Kuo; Iat-Hang Fong; Vijesh Kumar Yadav; Nicholas G Kounis; Patrick Hu; Ming-Yow Hung
Journal:  Oxid Med Cell Longev       Date:  2022-01-19       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.